Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis

This study is currently recruiting participants.

Verified by Radboud University, June 2008

Sponsored by:	Radboud University
Information provided by:	Radboud University
ClinicalTrials.gov Identifier:	NCT00184964

Purpose

CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.

This however has never been validated on a histological level. In this study patients with non small cell lung cancer and atelectasis who are eligible for surgery undergo a CT-scan and a PET-scan prior to surgery.

The resection specimen will be compared to the preoperative imaging.

Condition	Intervention
Carcinoma, Non Small Cell Lung	Procedure: CT-scan, PET-scan

MedlinePlus related topics: CT Scans Cancer Lung Cancer Nuclear Scans

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen

Further study details as provided by Radboud University:

Primary Outcome Measures:

Histological validation of CT-PET image fusion.

Estimated Enrollment:	15
Study Start Date:	June 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

-Patients with non small cell lung cancer and atelectasis, who are eligible for surgery.

Exclusion Criteria:

age < 18 years
pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184964

Contacts

Contact: Dominic A Schinagl, MD

+31243614515

d.schinagl@rther.umcn.nl

Locations

Netherlands, Gelderland
Radboud University Nijmegen Medical Centre	Recruiting
Nijmegen, Gelderland, Netherlands, 6500HB
Contact: Dominic A Schinagl, MD +31243614515 d.schinagl@rther.umcn.nl
Principal Investigator: Dominic A Schinagl, MD

Sponsors and Collaborators

Radboud University

Investigators

Study Director:

Jan Bussink, MD, PhD

Radiation oncologist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

More Information

Study ID Numbers:	2004/032
Study First Received:	September 12, 2005
Last Updated:	June 3, 2008
ClinicalTrials.gov Identifier:	NCT00184964
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Study placed in the following topic categories:

Thoracic Neoplasms
Atelectasis
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms

Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on January 14, 2009